Topix is the number one independent provider of professional skincare products in the United States. Topix develops, manufacturers and markets a differentiated portfolio of clinically-proven cosmetic and therapeutic skincare products sold across high-growth channels, including physician offices, professional spas, natural and premium retailers and direct-to-consumer. Topix’s family of brands include Replenix, DermaE, ClarityRx and custom brands developed in partnership with leading dermatologists. Topix is headquartered in New York where it maintains FDA-certified R&D and manufacturing capabilities and employs approximately 250 people.
New Mountain’s investment in Topix was driven by our firm’s multi-year and proactive “deep-dive” efforts in the life sciences, health & wellness, aesthetics, and niche consumer products sectors. New Mountain first began a dialogue with Topix’s founder and CEO in March 2015. Topix decided that New Mountain’s deep expertise in healthcare products as well as its focus on growth and business-building made it the ideal partner to help Topix continue its growth and achieve the next level of success. Throughout diligence, New Mountain was able to leverage its broad network of relationships with industry executives and physicians, developed through our “deep-dives,” to identify and evaluate multiple, significant growth opportunities. Topix and New Mountain ultimately completed the transaction on a fully proprietary and exclusive basis in July 2016.